...
首页> 外文期刊>Molecular pain >Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery
【24h】

Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery

机译:通过不同的交货途径重组腺相关病毒血清型6(RAAV2 / 6)介导的基因转移到伤害性神经元

获取原文
           

摘要

Background Gene transfer to nociceptive neurons of the dorsal root ganglia (DRG) is a promising approach to dissect mechanisms of pain in rodents and is a potential therapeutic strategy for the treatment of persistent pain disorders such as neuropathic pain. A number of studies have demonstrated transduction of DRG neurons using herpes simplex virus, adenovirus and more recently, adeno-associated virus (AAV). Recombinant AAV are currently the gene transfer vehicles of choice for the nervous system and have several advantages over other vectors, including stable and safe gene expression. We have explored the capacity of recombinant AAV serotype 6 (rAAV2/6) to deliver genes to DRG neurons and characterized the transduction of nociceptors through five different routes of administration in mice. Results Direct injection of rAAV2/6 expressing green fluorescent protein (eGFP) into the sciatic nerve resulted in transduction of up to 30% eGFP-positive cells of L4 DRG neurons in a dose dependant manner. More than 90% of transduced cells were small and medium sized neurons (< 700 μm2), predominantly colocalized with markers of nociceptive neurons, and had eGFP-positive central terminal fibers in the superficial lamina of the spinal cord dorsal horn. The efficiency and profile of transduction was independent of mouse genetic background. Intrathecal administration of rAAV2/6 gave the highest level of transduction (≈ 60%) and had a similar size profile and colocalization with nociceptive neurons. Intrathecal administration also transduced DRG neurons at cervical and thoracic levels and resulted in comparable levels of transduction in a mouse model for neuropathic pain. Subcutaneous and intramuscular delivery resulted in low levels of transduction in the L4 DRG. Likewise, delivery via tail vein injection resulted in relatively few eGFP-positive cells within the DRG, however, this transduction was observed at all vertebral levels and corresponded to large non-nociceptive cell types. Conclusion We have found that rAAV2/6 is an efficient vector to deliver transgenes to nociceptive neurons in mice. Furthermore, the characterization of the transduction profile may facilitate gene transfer studies to dissect mechanisms behind neuropathic pain.
机译:背景技术基因转移到背根神经节(DRG)的伤害性神经元是一种有希望的方法来对啮齿动物的疼痛机制进行解剖,是治疗持续疼痛障碍等神经病疼痛的潜在治疗策略。许多研究表明使用疱疹病毒,腺病毒和最近,腺相关病毒(AAV)进行转导DRG神经元。重组AAV目前是神经系统选择的基因转移载体,并且与其他载体具有若干优点,包括稳定和安全的基因表达。我们探索了重组AAV血清型6(RAAV2 / 6)的能力将基因传递给DRG神经元,并通过小鼠中的五种不同的给药途径进行了转导。结果将表达绿色荧光蛋白(EGFP)的RAAV2 / 6直接注射到坐骨神经中,导致L4 DRG神经元的高达30%EGFP阳性细胞以剂量依赖性方式进行转导。超过90%的转导细胞是中小型和中等大小的神经元(<700μm2),主要用伤害性神经元的标记分致成分,并且在脊髓背角的浅表椎板中具有EGFP阳性中央末端纤维。转导的效率和轮廓与小鼠遗传背景无关。 RAAV2 / 6的鞘内施用给出了最高水平的转导(≈60%),并且具有与伤害神经元的相似尺寸的曲线和分层化。鞘内给药还在宫颈和胸腔水平转导的DRG神经元,导致小鼠模型中的转导水平的神经病疼痛。皮下和肌肉内递送导致L4 DRG中的低水平转导。同样,通过尾静脉注射递送导致DRG内的相对较少的EGFP阳性细胞,然而,在所有椎体水平上观察到这种转导,并且对应于大的非伤害性细胞类型。结论我们发现RAAV2 / 6是一种有效的载体,以将转基因递送给小鼠的伤害性神经元。此外,转导谱的表征可以促进基因转移研究,以将机制疏忽化神经病疼痛。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号